SMT202000207T1 - Metodo per praparare amg 416 - Google Patents
Metodo per praparare amg 416Info
- Publication number
- SMT202000207T1 SMT202000207T1 SM20200207T SMT202000207T SMT202000207T1 SM T202000207 T1 SMT202000207 T1 SM T202000207T1 SM 20200207 T SM20200207 T SM 20200207T SM T202000207 T SMT202000207 T SM T202000207T SM T202000207 T1 SMT202000207 T1 SM T202000207T1
- Authority
- SM
- San Marino
- Prior art keywords
- amg
- preparing
- preparing amg
- Prior art date
Links
- ANIAZGVDEUQPRI-ZJQCGQFWSA-N etelcalcetide Chemical compound NC(N)=NCCC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](C)NC(=O)[C@@H](CSSC[C@H](N)C(O)=O)NC(C)=O ANIAZGVDEUQPRI-ZJQCGQFWSA-N 0.000 title 1
- 229950006502 etelcalcetide Drugs 0.000 title 1
- 108091022127 etelcalcetide hydrochloride Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Glass Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461974899P | 2014-04-03 | 2014-04-03 | |
| EP15773570.5A EP3126373B1 (en) | 2014-04-03 | 2015-04-03 | Method for preparing amg 416 |
| PCT/US2015/024347 WO2015154031A1 (en) | 2014-04-03 | 2015-04-03 | Method for preparing amg 416 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SMT202000207T1 true SMT202000207T1 (it) | 2020-05-08 |
Family
ID=54241346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM20200207T SMT202000207T1 (it) | 2014-04-03 | 2015-04-03 | Metodo per praparare amg 416 |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US10407464B2 (it) |
| EP (3) | EP3708576B1 (it) |
| JP (1) | JP6710158B2 (it) |
| KR (1) | KR102397271B1 (it) |
| CN (3) | CN119874825A (it) |
| AU (1) | AU2015240527B2 (it) |
| CA (1) | CA2944194C (it) |
| CL (1) | CL2016002513A1 (it) |
| CY (1) | CY1123100T1 (it) |
| DK (1) | DK3126373T3 (it) |
| EA (1) | EA032597B1 (it) |
| ES (2) | ES2786225T3 (it) |
| HR (1) | HRP20200527T1 (it) |
| HU (1) | HUE048489T2 (it) |
| IL (1) | IL248059B2 (it) |
| LT (1) | LT3126373T (it) |
| MA (2) | MA39628B1 (it) |
| ME (1) | ME03781B (it) |
| MX (1) | MX374205B (it) |
| PL (1) | PL3126373T3 (it) |
| PT (1) | PT3126373T (it) |
| RS (1) | RS60187B1 (it) |
| SG (1) | SG11201608176VA (it) |
| SI (1) | SI3126373T1 (it) |
| SM (1) | SMT202000207T1 (it) |
| WO (1) | WO2015154031A1 (it) |
| ZA (1) | ZA201606844B (it) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20160549A1 (es) | 2013-06-28 | 2016-06-15 | Amgen Inc | Formulacion liquida estable de etelcalcetida (amg 416) |
| WO2015154031A1 (en) | 2014-04-03 | 2015-10-08 | Amgen Inc. | Method for preparing amg 416 |
| CN106928321B (zh) * | 2015-12-31 | 2019-07-26 | 深圳翰宇药业股份有限公司 | 一种合成Etelcalcetide的方法 |
| CN106928320B (zh) * | 2015-12-31 | 2021-01-15 | 深圳翰宇药业股份有限公司 | 一种合成Etelcalcetide的方法 |
| JP6991196B2 (ja) * | 2016-03-23 | 2022-02-03 | バッヘン・ホールディング・アクチエンゲゼルシャフト | グルカゴン様ペプチドを製造するための方法 |
| US10858390B2 (en) | 2016-09-02 | 2020-12-08 | Cem Corporation | Use of excess carbodiimide for peptide synthesis at elevated temperatures |
| CN108101959B (zh) * | 2016-11-24 | 2021-07-09 | 四川科伦药物研究院有限公司 | 一种制备高纯度多肽或其类似物的方法 |
| CN106928171B (zh) * | 2017-05-03 | 2019-08-13 | 成都郑源生化科技有限公司 | Fmoc-Arg(Pbf)-OH的合成方法 |
| TW201915009A (zh) * | 2017-10-03 | 2019-04-16 | 中化合成生技股份有限公司 | 合成依特卡肽(Etelcalcetide)或其鹽類之方法 |
| CN110498835B (zh) * | 2018-05-17 | 2021-06-08 | 深圳翰宇药业股份有限公司 | 一种合成etelcalcetide的方法 |
| CN109280078B (zh) * | 2018-10-30 | 2019-06-25 | 成都诺和晟泰生物科技有限公司 | 一种制备维拉卡肽的方法 |
| CN112062811B (zh) * | 2019-06-10 | 2022-03-25 | 深圳翰宇药业股份有限公司 | 一种维拉卡肽的合成方法 |
| US20220298206A1 (en) * | 2019-08-26 | 2022-09-22 | Auro Peptides Ltd | An improved process for the preparation of Etelcalcetide Hydrochloride |
| EP3875466A1 (en) * | 2020-03-05 | 2021-09-08 | Fresenius Kabi iPSUM S.r.l. | Process for the synthesis of etelcalcetide |
| WO2021246471A1 (ja) | 2020-06-03 | 2021-12-09 | 中外製薬株式会社 | 高難度配列の効率的ペプチド縮合法 |
| CN111925415A (zh) * | 2020-08-10 | 2020-11-13 | 海南中和药业股份有限公司 | 一种维拉卡肽杂质的制备方法 |
| TWI792442B (zh) | 2021-07-23 | 2023-02-11 | 建誼生技股份有限公司 | 依特卡肽鹽酸鹽之製造方法 |
| CN114524860B (zh) * | 2021-12-29 | 2025-01-24 | 深圳翰宇药业股份有限公司 | 一种Etelcalcetide的合成方法及其应用 |
| WO2026093598A1 (en) * | 2024-11-04 | 2026-05-07 | SelectION Therapeutics GmbH | Peptide with low content of d-cys38 epimer |
| WO2026093602A1 (en) * | 2024-11-04 | 2026-05-07 | SelectION Therapeutics GmbH | D-cys38 epimer of kv1.3 inhibitor |
| CN120699096B (zh) * | 2025-07-07 | 2026-01-23 | 苏州天马医药集团天吉生物制药有限公司 | 一种依特卡肽的制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
| EP0339695A3 (en) | 1988-04-29 | 1990-05-30 | Stichting Voor De Technische Wetenschappen | A process for preparing an antigenic or immunogenic conjugate as well as the use of such conjugates |
| SE9603465D0 (sv) | 1996-09-23 | 1996-09-23 | Astra Ab | New compounds |
| NO311807B1 (no) | 1999-03-04 | 2002-01-28 | Bionor Immuno As | HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV |
| JP5473925B2 (ja) | 2007-10-27 | 2014-04-16 | コーデン ファーマ コロラド インコーポレイテッド | 固相および溶液相の組み合わせ技法を使用するインスリン分泌性ペプチドの合成 |
| CN101250172B (zh) | 2008-03-07 | 2012-05-02 | 上海瀚鸿化工科技有限公司 | 精氨酸双保护制备工艺 |
| WO2010129520A1 (en) | 2009-05-06 | 2010-11-11 | Mallinckrodt Inc. | Solid support for fmoc-solid phase synthesis of peptide acids |
| EP2459208B1 (en) * | 2009-07-29 | 2016-09-28 | Kai Pharmaceuticals, Inc. | Therapeutic agents for reducing parathyroid hormone levels |
| WO2011133346A1 (en) * | 2010-04-21 | 2011-10-27 | Pharmacofore, Inc. | Peripheral opioid agonists and peripheral opioid antagonists |
| WO2012031327A1 (en) * | 2010-09-08 | 2012-03-15 | Howard Florey Institute Of Experimental Physiology And Medicine | Modified relaxin polypeptides |
| WO2013042129A1 (en) | 2011-09-23 | 2013-03-28 | Natco Pharma Limited | Improved process for preparation of bivalirudin |
| PE20160549A1 (es) | 2013-06-28 | 2016-06-15 | Amgen Inc | Formulacion liquida estable de etelcalcetida (amg 416) |
| WO2015154031A1 (en) | 2014-04-03 | 2015-10-08 | Amgen Inc. | Method for preparing amg 416 |
| CN105504012A (zh) * | 2014-09-30 | 2016-04-20 | 深圳翰宇药业股份有限公司 | 一种多肽的制备方法 |
| CN107434820A (zh) * | 2017-08-07 | 2017-12-05 | 南京工业大学 | 一种维拉卡肽的合成方法 |
-
2015
- 2015-04-03 WO PCT/US2015/024347 patent/WO2015154031A1/en not_active Ceased
- 2015-04-03 SI SI201531173T patent/SI3126373T1/sl unknown
- 2015-04-03 PT PT157735705T patent/PT3126373T/pt unknown
- 2015-04-03 AU AU2015240527A patent/AU2015240527B2/en active Active
- 2015-04-03 HU HUE15773570A patent/HUE048489T2/hu unknown
- 2015-04-03 CA CA2944194A patent/CA2944194C/en active Active
- 2015-04-03 RS RS20200448A patent/RS60187B1/sr unknown
- 2015-04-03 ES ES15773570T patent/ES2786225T3/es active Active
- 2015-04-03 MX MX2016012965A patent/MX374205B/es active IP Right Grant
- 2015-04-03 DK DK15773570.5T patent/DK3126373T3/da active
- 2015-04-03 HR HRP20200527TT patent/HRP20200527T1/hr unknown
- 2015-04-03 IL IL248059A patent/IL248059B2/en unknown
- 2015-04-03 ME MEP-2020-83A patent/ME03781B/me unknown
- 2015-04-03 JP JP2016560462A patent/JP6710158B2/ja active Active
- 2015-04-03 EP EP20160369.3A patent/EP3708576B1/en active Active
- 2015-04-03 PL PL15773570T patent/PL3126373T3/pl unknown
- 2015-04-03 EP EP23150870.6A patent/EP4219526A3/en not_active Withdrawn
- 2015-04-03 EA EA201692001A patent/EA032597B1/ru not_active IP Right Cessation
- 2015-04-03 SG SG11201608176VA patent/SG11201608176VA/en unknown
- 2015-04-03 MA MA39628A patent/MA39628B1/fr unknown
- 2015-04-03 CN CN202510112970.9A patent/CN119874825A/zh active Pending
- 2015-04-03 US US15/300,209 patent/US10407464B2/en active Active
- 2015-04-03 KR KR1020167030590A patent/KR102397271B1/ko active Active
- 2015-04-03 MA MA052906A patent/MA52906A/fr unknown
- 2015-04-03 ES ES20160369T patent/ES2943671T3/es active Active
- 2015-04-03 SM SM20200207T patent/SMT202000207T1/it unknown
- 2015-04-03 CN CN201580029560.2A patent/CN106795201A/zh active Pending
- 2015-04-03 LT LTEP15773570.5T patent/LT3126373T/lt unknown
- 2015-04-03 EP EP15773570.5A patent/EP3126373B1/en active Active
- 2015-04-03 CN CN202510112966.2A patent/CN119899242A/zh active Pending
-
2016
- 2016-10-03 CL CL2016002513A patent/CL2016002513A1/es unknown
- 2016-10-05 ZA ZA2016/06844A patent/ZA201606844B/en unknown
-
2019
- 2019-08-05 US US16/532,344 patent/US11377474B2/en active Active
-
2020
- 2020-04-29 CY CY20201100391T patent/CY1123100T1/el unknown
-
2022
- 2022-06-28 US US17/852,263 patent/US20230099078A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201606844B (en) | Method for preparing amg 416 | |
| PL3183349T3 (pl) | Sposób przygotowania Rebaudiozydu I | |
| GB201406151D0 (en) | Method | |
| GB201408119D0 (en) | Method | |
| GB201406155D0 (en) | Method | |
| GB201410262D0 (en) | Novel method | |
| PL3196196T3 (pl) | Sposób wytwarzania kalcobutrolu | |
| IL250682A0 (en) | A method for the preparation of 2'-o-fucosyl lactose | |
| SG11201703689SA (en) | Method | |
| GB201403470D0 (en) | Method | |
| SG11201701326YA (en) | Method for producing oligosilane | |
| PT3169844T (pt) | Método para prevenir a formação de incrustação | |
| IL252173A0 (en) | Methods for the production of methyl dichlorophosphane | |
| ZA201903463B (en) | Method for preparing hexadecahydropyrene | |
| GB201409128D0 (en) | Method | |
| GB2538030B (en) | Up-drawing casting method | |
| GB201409101D0 (en) | Method | |
| GB201408649D0 (en) | Method | |
| GB201407971D0 (en) | Method | |
| SG11201608114QA (en) | Method for producing tri-carbobenzoxy-arginine | |
| GB201401565D0 (en) | Novel method | |
| GB201409127D0 (en) | Method | |
| GB201409067D0 (en) | Method | |
| GB201408160D0 (en) | Method | |
| GB201407948D0 (en) | Method |